Glomerular Disease

์‚ฌ๊ตฌ์ฒด(glomerulus) ์ •์ƒ ๊ตฌ์กฐ

์‚ฌ๊ตฌ์ฒด ๋ฒฝ์€ size, charge-selective barrier๋กœ, ์ผ์ • ํฌ๊ธฐ ์ด์ƒ์ด๊ฑฐ๋‚˜ ์Œ์ „ํ•˜๋ฅผ ๋ค ๋ฌผ์งˆ์€ ์—ฌ๊ณผ ์žฅ๋ฒฝ์„ ์ž˜ ๋น ์ ธ๋‚˜๊ฐ€์ง€ ๋ชปํ•œ๋‹ค.

[๊ตฌ์กฐ]

  • Capillary endothelium
  • Glomerular basement membrane (GBM)
  • Podocytes (visceral epithelial cells)

* Juxtaglomerular apparatus (์‚ฌ๊ตฌ์ฒด์˜†์žฅ์น˜) : ์‚ฌ๊ตฌ์ฒด ์—ฌ๊ณผ์œจ ์กฐ์ ˆ, ํ˜ธ๋ฅด๋ชฌ(renin ๋“ฑ) ๋ถ„๋น„

  • mesengial cells, juxtaglomerular cell, macula densa ๋“ฑ ์‚ฌ๊ตฌ์ฒด ์ฃผ๋ณ€์— ์กด์žฌํ•˜๋Š” ์„ธํฌ๋“ค์˜ ์ด์นญ.

1. ์‚ฌ๊ตฌ์ฒด ์งˆํ™˜์˜ ๋ถ„๋ฅ˜

๊ณ ์–‘์ด๋ณด๋‹ค ๊ฐœ์—์„œ ๋” ํ”ํ•˜๋‹ค.

Classical classification

์‹ ์žฅ ์ž์ฒด์˜ ๋ฌธ์ œ์ธ์ง€, ๋‹ค๋ฅธ ์ „์‹ ์  ์งˆํ™˜ ๋•Œ๋ฌธ์ธ์ง€.

  • Primary glomerular disease
  • Secondary glomerular disease
    • Immune complex deposition (๋ฉด์—ญ๋ณตํ•ฉ์ฒด ์นจ์ „)
    • Systemic factors affecting the glomeruli (~63%)
      • Neoplastic, infectious, or noninfectious inflammatory (NIN) disorders
Biopsy evaluation-based classificiation

์ตœ๊ทผ์—๋Š” ์‹ ์žฅ ์ƒ๊ฒ€์„ ํ†ตํ•ด ๊ตฌ๋ถ„ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์ผ๋ฐ˜์ ์ด๋‹ค.

  • Immune complex-mediated glomerulonephritis (ICGN) : 48%
  • Amyloidosis : 15% (* ํŠนํžˆ Shar-pei ์ข…์—์„œ ๋งŽ์ด ๋ณด๊ณ ๋จ.)
  • Non-ICGN : 37%

Glomerulonephritis์˜ Etiology

  • Idiopathic (ํŠน๋ฐœ์„ฑ)
  • Noninfectious inflammatory disease (NIN)
  • Neoplasia
  • Familial predisposition to immune complex formation and deposition
    • Soft-coated Wheaten Terrier, Bernese Mountain Dog, Brittany Spaniel

1๏ธโƒฃ Immune complex-mediated glomerulonephritis (ICGN)

  • ์‚ฌ๊ตฌ์ฒด ๋‚ด๋ถ€์— ๋ฉด์—ญ๋ณตํ•ฉ์ฒด๊ฐ€ ์นจ์ „๋˜์–ด ๋ฐœ์ƒํ•˜๋Š” ์‚ฌ๊ตฌ์ฒด์‹ ์—ผ.
  • ๋ฐœ์ƒ ๊ณผ์ •
    • (1) Immune complex deposition in glomeruli : ๋ฉด์—ญ๋ณตํ•ฉ์ฒด๊ฐ€ ์นจ์ „๋œ๋‹ค
    • (2) Glomerular damage : ์‚ฌ๊ตฌ์ฒด ๋ง‰์˜ ์Œ์ „ํ•˜๊ฐ€ ์†Œ์‹ค๋˜๊ณ , pore๊ฐ€ ๋„“์–ด์ง„๋‹ค โ†’ ๊ฑฐ๋Œ€ ๋ถ„์ž๊ฐ€ ๊ณผ๋„ํ•˜๊ฒŒ ์—ฌ๊ณผ๋œ๋‹ค โ†’ ์—ผ์ฆ ๋ฐœ์ƒ
    • (3) Glomerular sclerosis : ๋‹ค๋ฐœ์„ฑ ๊ฒฝํ™”์ฆ(sclerosis), ๋งŒ์„ฑ ์‹ ๋ถ€์ „ ๋ฐœ์ƒ
    • ๋‹จ๋ฐฑ๋‡จ, ๊ณ ํ˜ˆ์••, ํ˜ˆ์ „/์ƒ‰์ „์ฆ๋„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค.
  • podocyte ์•„๋ž˜, ๋‚ดํ”ผ์„ธํฌ, ์„ธํฌ๋ง‰ ๋“ฑ ๋ชจ๋“  ์ธต์— ์นจ์ „๋  ์ˆ˜ ์žˆ๋‹ค.

SLE (Systemic lupus erythematosus)

  • ์‹ ์ฒด์˜ ๋ฉด์—ญ ์‹œ์Šคํ…œ์ด ์‹ ์ฒด ๊ณณ๊ณณ์˜ ๊ฑด๊ฐ•ํ•œ ์กฐ์ง์„ ์ž˜๋ชป ๊ณต๊ฒฉํ•˜๋Š” ์ž๊ฐ€๋ฉด์—ญ์งˆํ™˜
  • SLE์˜ ๊ฐ๋ณ„์ง„๋‹จ ๋ชฉ๋ก ์ค‘ GN๋„ ์žˆ์Œ.
  • ์ „์‹  ๋ฐœ์—ด, ๋‹ค๋ฐœ์„ฑ ๊ด€์ ˆ์—ผ, ๋นˆํ˜ˆ ๋“ฑ์ด ์‹ ์—ผ๊ณผ ํ•จ๊ป˜ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝ์šฐ, SLE ๊ฐ๋ณ„์ง„๋‹จ์ด ํ•„์š”ํ•จ.

CLE (Cutaneous lupus erythematosus)

  • LE-specific skin disease
  • DLE : Discoid lupus erythematosus
  • ECLE : Exfoliative cutaneous lupus erythematosus

2๏ธโƒฃ Amyloidosis

  • Amyloid(๋น„์ •์ƒ์ ์œผ๋กœ ์ ‘ํžŒ ๋‹จ๋ฐฑ์งˆ ์‘์ง‘์ฒด)๊ฐ€ ์‹ ์ฒด ๊ณณ๊ณณ์— ์นจ์ฐฉ๋˜๋Š” ์งˆํ™˜.
  • ๊ณผ๋„ํ•˜๊ฒŒ ์นจ์ฐฉ๋  ์‹œ ์ •์ƒ ๋‹จ๋ฐฑ์งˆ์ด ๋ณ€์ด๋˜์–ด ๊ธฐ๋Šฅ ์ด์ƒ์„ ์ดˆ๋ž˜ํ•จ.
Classification by distribution (๋ถ„ํฌ์— ๋”ฐ๋ฅธ ๊ตฌ๋ถ„)
  • Systemic amyloidosis : 2๊ฐœ ์ด์ƒ์˜ ๊ธฐ๊ด€์—์„œ ๋ฐœ์ƒํ•˜๋Š” ์ „์‹ ์ ์ธ ํ˜•ํƒœ๋กœ, ํ”ํ•จ.

  • Localized amyloidosis (uncommon) : 1๊ฐœ์˜ ๊ธฐ๊ด€์—๋งŒ ์˜ํ–ฅ.

    • Islet amyloidosis (cats) : ์ทŒ์žฅ์˜ ๋ž‘๊ฒŒ๋ฅดํ•œ์Šค์„ฌ์— ์•„๋ฐ€๋กœ์ด๋“œ๊ฐ€ ์นจ์ฐฉ๋œ ๊ฒฝ์šฐ.
      • ์ทŒ์žฅ์—์„œ ์ธ์А๋ฆฐ ๊ณผ๋‹ค ๋ถ„๋น„ โ†’ ์•„๋ฐ€๋ฆฐ ๊ณผ๋‹ค ๋ถ„๋น„ โ†’ ์•„๋ฐ€๋กœ์ด๋“œ ์ถ•์  โ†’ ฮฒ cell apoptosis โ†’ ์ œโ…กํ˜• ๋‹น๋‡จ ์œ ๋ฐœ
  • ๋Œ€๋ถ€๋ถ„ ๊ด‘๋ฒ”์œ„ํ•˜๊ฒŒ ์ฒœ์ฒœํžˆ ์ง„ํ–‰๋˜๋ฉฐ, ์•Œ์•„์ฐจ๋ ธ์„ ๋• ์ด๋ฏธ ๋Šฆ์€ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์Œ.

  • ์ƒ๊ฒ€์„ ํ•˜์ง€ ์•Š๋Š” ์ด์ƒ ์ง„๋‹จ์ด ์–ด๋ ค์›€.

  • ํŠน์ •ํ•œ ์น˜๋ฃŒ๋ฒ•์ด ์—†์Œ.

Classification by the nature of the responsible protein (์›์ธ ๋‹จ๋ฐฑ์งˆ์— ๋”ฐ๋ฅธ ๊ตฌ๋ถ„)
  • Secondary reactive (AA) amyloidosis
    • serum amyloid A (SAA) ๋‹จ๋ฐฑ์งˆ์ด ์นจ์ฐฉ๋˜์–ด ๋ฐœ์ƒ.
    • ๊ฐ์—ผ, ์‹ฌ๊ฐํ•œ ์—ผ์ฆ ๋˜๋Š” ๋ฉด์—ญ ๊ด€๋ จ ์ƒํƒœ, ์ข…์–‘ ๋“ฑ์˜ ์ž๊ทน์— ์˜ํ•ด ๊ธ‰์„ฑ๊ธฐ ๋‹จ๋ฐฑ์งˆ์ธ SAA๊ฐ€ ๊ณผ๋„ํ•˜๊ฒŒ ํ˜•์„ฑ๋˜์–ด ์นจ์ฐฉ๋จ.
    • ๊ฐœ์—์„œ ํ”ํ•จ.
    • ์ฃผ๋กœ ์‹ ์žฅ์— ๋งŽ์ด ์นจ์ฐฉ๋จ โ†’ ์‹ ๋ถ€์ „ ์œ ๋ฐœ. (*Shar-pei, Siamese : ๊ฐ„์— ์นจ์ฐฉ๋˜๋Š” ์ผ์ด ํ”ํ•จ.)
  • Primary (AL) amyloidosis (rare)
    • Light chain Ig ๋‹จ๋ฐฑ์งˆ์ด ์นจ์ฐฉ.
    • ํŠน์ • ์ข…์–‘์ด ์ž๊ทน์›์ด ๋˜์–ด ๋‚˜ํƒ€๋‚จ. ์‹ ๊ฒฝ, ๊ด€์ ˆ ๋ถ€์œ„์— ์ฃผ๋กœ ์นจ์ฐฉ๋จ.

3. Clinical features

(1) Prediposition (์†Œ์ธ)

Age

  • Glomerular disease : ๊ฐœ๋Š” 4-8์„ธ, ๊ณ ์–‘์ด๋Š” 3-4์„ธ์— ๋งŽ์ด ๋ฐœ๋ณ‘ (๊ณ ์–‘์ด๊ฐ€ ์ข€ ๋” ์–ด๋ฆด ๋•Œ ๋ฐœ๋ณ‘)
  • ICGN : ๊ฐœ์—์„œ 6.5-7์„ธ (์ข€ ๋” ์ค‘๋…„์— ๋ฐœ๋ณ‘)
  • Amyloidosis
    • non-familial form : ์ค‘๋…„~๋…ธ๋…„๋ น์˜ ๊ฐœ์™€ ๊ณ ์–‘์ด
    • familial amyloidosis (๊ฐ€์กฑ๋ ฅ) : 5-11์„ธ (Beagle), 1-6์„ธ (Shar-pei)

Sex

  • Glomerular disease : GN ๊ณ ์–‘์ด์˜ 75%๊ฐ€ male / ๊ฐœ์—์„œ๋Š” ์—†์Œ

Breed

๋งํฌ๋Š” ๊ทธ๋ƒฅ ๊ฐ•์•„์ง€๋“ค ์‚ฌ์ง„ใ…Žใ…Ž

(2) Common features

  • ์ž„์ƒ ์ฆ์ƒ์€ ๋งค์šฐ ๋‹ค์–‘ํ•˜๋‹ค - ๋‹จ๋ฐฑ๋‡จ๋‚˜ ์‹ ์žฅ ์งˆํ™˜์˜ ์ •๋„, ๋‹ค๋ฅธ ์ „์‹  ์ด์ƒ์˜ ์—ฌ๋ถ€๋ฅผ ๋ณด๊ณ  ๊ตฌ๋ถ„.
  • Anorexia, weight loss, lethargy (๊ธฐ๋ ฅ ์ €ํ•˜, ์‹์š• ๋ถ€์ง„)
  • polyuria, polydipsia (๋‹ค์Œ๋‹ค๋‡จ; ์‹ ์žฅ ๊ธฐ๋Šฅ์ด ๋งŽ์ด ๋–จ์–ด์ง)
  • Vomiting, diarrhea (๊ตฌํ† ์„ค์‚ฌ)
  • Halitosis (๊ตฌ์ทจ)

other clinical signs

  • Fluid retention์œผ๋กœ ์ธํ•ด โ†’ ๋ณต์ˆ˜(ascties)์™€ ํ•จ๊ป˜ ๋ณต๋ถ€ ํŒฝ์ฐฝ, ๋ง์ดˆ๋ถ€์ข…
  • Thromboembolism์œผ๋กœ ์ธํ•ด โ†’ ํ์ƒ‰์ „์ฆ(pulmonary embolism)๊ณผ ํ•จ๊ป˜ ๊ฐ‘์ž‘์Šค๋Ÿฐ ํ˜ธํก๊ณค๋ž€(dyspnea), iliac์˜ ๊ฐ‘์ž‘์Šค๋Ÿฐ ๋งˆ๋น„(paraparesis), ๋„™๋‹ค๋ฆฌ๋™๋งฅ ์ƒ‰์ „์ฆ(femoral artery embolism)
  • Hypertension์œผ๋กœ ์ธํ•ด โ†’ acute blindness, cardiac murmur, ์ตœ๊ทผ ๋ฐœ์ƒํ•œ ์‹ ๊ฒฝํ•™์  ์ฆ์ƒ

4. Diagnosis

(1) Baseline Diagnostics

๊ธฐ์ค€
Signalmentํ˜ธ๋ฐœ ํ’ˆ์ข…, ์—ฐ๋ น, ์„ฑ๋ณ„ ๋“ฑ
๋ฌธ์ง„ ์ฒญ์ทจnephrotoxin ์„ญ์ทจ/๋…ธ์ถœ ์—ฌ๋ถ€
- ํฌ๋„, ๊ฑดํฌ๋„(raisins)
- ์—ํ‹ธ๋ Œ ๊ธ€๋ฆฌ์ฝœ (๋ถ€๋™์•ก)
- NSAIDs
- ์•„์„ธํŠธ์•„๋ฏธ๋…ธํŽœ
์‹ ์ฒด ๊ฒ€์‚ฌBCS, BP, ์‹ ์žฅ ์ด‰์ง„, ๊ตฌ๊ฐ•/๊ฐ๋ง‰/ํ”ผ๋ถ€/์ง์žฅ ๊ฒ€์‚ฌ
- Poor body condition
- ํƒˆ์ˆ˜, ๊ณ ํ˜ˆ์••
- ํ˜ธํก๊ณค๋ž€, ๋งฅ๋ฐ•์˜ ๊ฐ์†Œ ๋˜๋Š” ์†Œ์‹ค
์š”๊ฒ€์‚ฌ (Urinalysis)- ๋šœ๋ ทํ•œ ์นจ์ „๋ฌผ ์—†์ด ์ง€์†์ ์ธ ๋‹จ๋ฐฑ๋‡จ
- UPC > 1 (๋ณดํ†ต >2)
- USG : 1.007-1.015 (๋“ฑ์žฅ๋‡จ) : ๋„คํ”„๋ก  67% ์ด์ƒ ์†์‹ค ์‹œ
(* > 1.035 ์ผ ์ˆ˜๋„ : 40% ์ •๋„ ์†์‹ค๊นŒ์ง€๋Š” ๋ณด์ƒ ์ž‘์šฉ)
- Cylindruria (์›์ฃผ๋‡จ) : hyaline casts ๋“ฑ
CBC- ๋น„์žฌ์ƒ์„ฑ ๋นˆํ˜ˆ (Nonregenerative anemia)
- ํ˜ˆ์†ŒํŒ์ฆ๊ฐ€์ฆ (Thrombocytosis) / Thrombocytopenia
- ๊ณ ์„ฌ์œ ์†Œ์›ํ˜ˆ์ฆ (Hyperfibrinogenemia)
Serum chemistry- Azotemia ( ~50%)
- Hyperphosphatemia
- Hypoalbuminemia (์ €์•Œ๋ถ€๋ฏผํ˜ˆ์ฆ) โ†’ Hypoproteinemia
- Hypercholesterolemia (๊ณ ์ฝœ๋ ˆ์Šคํ…Œ๋กคํ˜ˆ์ฆ; ํ˜ธ๋ฅด๋ชฌ ์งˆํ™˜์—์„œ ํ”ํ•จ)
- Metabolic acidosis (๋Œ€์‚ฌ์„ฑ ์‚ฐ์ฆ)
+) Additional- TEG (Thromboelastography) ๊ฒ€์‚ฌ : ๊ณผ์‘๊ณ ์ƒํƒœ (ํ˜ˆ์ „ ํ˜•์„ฑ ์ž˜ ๋จ)

Proteinuria - ๋‹จ๋ฐฑ๋‡จ๊ฐ€ ๋‚˜ํƒ€๋‚˜๋Š” ์›์ธ

  • Localization(์œ ๋ฐœ๋œ ๊ณณ), Persistence(์–ผ๋งˆ๋‚˜ ์ง€์†), Magnitude(์‹ฌ๊ฐํ•œ ์ •๋„)์— ๋”ฐ๋ผ ํŒ๋‹จํ•œ๋‹ค.
    • Pre-glomerular proteinuria : ์ˆœํ™˜ํ•˜๋Š” ๋‹จ๋ฐฑ์งˆ ์ž์ฒด์˜ ์ฆ๊ฐ€๋กœ ๋ฐœ์ƒ (์ˆ˜ํ˜ˆ, myeloma)
    • Glomerular proteinuria : ์‚ฌ๊ตฌ์ฒด ๊ธฐ๋Šฅ์˜ ๊ฐ์†Œ(์„ ์ฒœ์ , ๋ฉด์—ญ๋งค๊ฐœ, ์•„๋ฐ€๋กœ์ด๋“œ ์ถ•์  ๋“ฑ) โ†’ ๋‹จ๋ฐฑ์งˆ์ด ๋น„์ •์ƒ์ ์œผ๋กœ ์—ฌ๊ณผ๋จ
      • Protein-losing nephropathy (PLN) : ์‚ฌ๊ตฌ์ฒด๋ณ‘์ฆ์— ์˜ํ•ด ๋‹จ๋ฐฑ์งˆ์ด ์†Œ์‹ค๋˜๋Š” ๊ฒƒ (์—ฌ๊ณผ๊ฐ€ ์ œ๋Œ€๋กœ ๋˜์ง€ ์•Š์•„ ํ˜ˆ์ค‘ ๋‹จ๋ฐฑ์งˆ๊ณผ ํ˜ˆ์žฅ ์„ฑ๋ถ„๊นŒ์ง€ ์†Œ๋ณ€์œผ๋กœ ๋น ์ ธ๋‚˜๊ฐ)
    • Post-glomerular proteinuria : ํ•˜๋ถ€ ์š”๋กœ๊ณ„์˜ ์—ผ์ฆ, ์ข…์–‘์œผ๋กœ ๋ฐœ์ƒ

UPC (Urine protein/creatinine) ratio

  • ๋ณดํ†ต ๊ฐœ๋Š” ~0.5, ๊ณ ์–‘์ด๋Š” ~0.4 ๊นŒ์ง€๊ฐ€ reference range.
  • UPC ์ฆ๊ฐ€์˜ ์ •๋„๋Š” ์–ด๋–ค ์‚ฌ๊ตฌ์ฒด ์งˆํ™˜์ธ์ง€์— ๋Œ€๋žต์ ์œผ๋กœ ์—ฐ๊ด€์„ฑ์ด ์žˆ๋‹ค(roughly correlated).
    • with GN (glomerulonephritis) : variable (์ •์ƒ์—์„œ > 30 ๊นŒ์ง€)
    • with glomerular amyloidosis : ์ข…์ข… > 10
    • with intestitial renal disease : ๋ณดํ†ต < 10
  • ํ˜ˆ๋‡จ(hematuria)๋‚˜ ๋†๋‡จ(pyuria)๊ฐ€ ์žˆ์œผ๋ฉด ์œ„์–‘์„ฑ์ด ๋‚˜์˜ฌ ์ˆ˜ ์žˆ๋‹ค.
  • ์‚ฌ๊ตฌ์ฒด ์งˆํ™˜์ด ์ง€์†๋˜๋ฉด โ†’ ์‚ฌ๊ตฌ์ฒด ์—ฌ๊ณผ์œจ์ด ๊ฐ์†Œ โ†’ ์—ฌ๊ณผ๋˜๋Š” ๋‹จ๋ฐฑ์งˆ๋Ÿ‰์ด ๊ฐ์†Œํ•˜์—ฌ UPC๊ฐ€ ๊ฐ์†Œํ•˜๊ณ  ์งˆ์†Œํ˜ˆ์ฆ(azotemia)์ด ์•…ํ™”๋  ์ˆ˜ ์žˆ๋‹ค. (UPC๊ฐ€ ๊ฐ์†Œํ–ˆ๋‹ค๊ณ  ๊ฐœ์„ ๋œ ๊ฒƒ์ด ์•„๋‹˜)

โ—Nephrotic syndrome (์‹ ์ฆํ›„๊ตฐ)

  • ์‹ ์žฅ ์†์ƒ์œผ๋กœ ์‹ฌ๊ฐํ•œ ์ฆ์ƒ๋“ค์ด ์ดˆ๋ž˜๋œ ๊ฒฝ์šฐ(A collection of symptoms due to kidney damage) - ์ ๊ทน์ ์ธ ์น˜๋ฃŒ ํ•„์š”
    • Marked proteinuria (์‹ฌํ•œ ๋‹จ๋ฐฑ๋‡จ)
    • Hypoalbuminemia (์ €์•Œ๋ถ€๋ฏผํ˜ˆ์ฆ; ์ฒด๋‚ด ๋‹จ๋ฐฑ์งˆ ์†Œ์‹ค)
    • Hypercholesterolemia (๊ณ ์ฝœ๋ ˆ์Šคํ…Œ๋กคํ˜ˆ์ฆ โ†’ ๊ณ ์ง€ํ˜ˆ์ฆ, ํ˜ˆ์ „์ฆ ๋ฐœ์ƒ ๊ฐ€๋Šฅ)
    • Edema / other abnormal fluid accumulation (์ˆ˜๋ถ„์ด ํ˜ˆ๊ด€ ๋ฐ–์œผ๋กœ ๋น ์ ธ๋‚˜์™€ ๋ถ€์ข… ์œ ๋ฐœ)
  • ์‚ฌ๊ตฌ์ฒด์‹ ์—ผ(GN) ํ™˜์ž์˜ 10~15%์—์„œ ์‹ ์ฆํ›„๊ตฐ ๋ฐœ์ƒ
  • ์งˆ์†Œํ˜ˆ์ฆ(azotemia)์ด ์‹ฌํ•œ ๊ฒฝ์šฐ์—๋Š” ์˜ˆํ›„๊ฐ€ ๋ถˆ๋Ÿ‰ํ•˜๋‹ค.
  • ์„ธ๊ท  ๊ฐ์—ผ์— ์ทจ์•ฝํ•ด์ ธ ๋ณต๋ง‰์—ผ, ๋ด‰์™€์ง์—ผ(cellulitis) ๋“ฑ์ด ๋ฐœ์ƒ ๊ฐ€๋Šฅ

(2) Imaging

์˜์ƒ ๊ฒ€์‚ฌ๋Š” ์‹ ์žฅ ์ž์ฒด์— ๋Œ€ํ•œ ๊ฒ€์‚ฌ๋ณด๋‹ค๋Š” ๊ฐ์—ผ, ์ข…์–‘, ๊ธฐ์ € ์งˆํ™˜ ํ™•์ธ์˜ ๋ชฉ์ ์œผ๋กœ ์ด์šฉ.

Radiographs (Thx. and Abd.)
- ๋‹ค์–‘ํ•œ ์‹ ์žฅ ํฌ๊ธฐ (variable kidney size)
ใ€€: Enlarged, small, irregular or (often) normal
- ์ฒด์•ก ์ €๋ฅ˜ : pleural effusion(ํ‰์ˆ˜), ascites(๋ณต์ˆ˜)
U/S - Kidney assessment (non-specific)
- ๋‹ค์–‘ํ•œ ์‹ ์žฅ ํฌ๊ธฐ (variable size)
- ์‹ ์žฅ ํ”ผ์งˆ๊ณผ ์ˆ˜์งˆ์˜ ๊ฒฝ๊ณ„ ์†Œ์‹ค (loss of corticomedullary distinction)
- ํ”ผ์งˆ์˜ ๊ณ ์—์ฝ”์„ฑ ๋ณ€ํ™” (increased echogenicity of the cortex) : ์ •์ƒ๋ณด๋‹ค ๋ฐ๊ฒŒ ๋ณด์ž„
- ๋‹ค์Œ/๋‹ค๋‡จ ์‹œ ์‹ ์šฐ ํ™•์žฅ (dilated renal pelvis - if polydipsic/polyuric)

(3) Histopathology

5. Treatment

Treatment goal

  • ๊ธฐ์ €์— ์žˆ๋Š”(underlying) ๊ฐ์—ผ์„ฑ, ์—ผ์ฆ์„ฑ, ์ข…์–‘์„ฑ ์งˆํ™˜๊นŒ์ง€ ํ™•์ธํ•˜๊ณ  ๊ต์ •ํ•˜๋Š” ๊ฒƒ
  • UPC ratio๋ฅผ 0.5 ์ดํ•˜ ํ˜น์€ ์ตœ์†Œ 50%๊นŒ์ง€ ์ค„์ด๋Š” ๊ฒƒ
    • ๋‹จ๋ฐฑ๋‡จ๊ฐ€ 3, 4 ์ด์ƒ์œผ๋กœ ์ง€์†๋  ๊ฒฝ์šฐ ๊ณผ์‘๊ณ  ์ƒํƒœ ์œ ๋ฐœ โ†’ ์ถ”๊ฐ€์ ์ธ ์‹ ์žฅ ์†์ƒ ๊ฐ€๋Šฅ
์š”์•ฝ
Standard treatment
โ‘  ์‹์ด ๊ด€๋ฆฌ (dietary management)
โ‘ก ๊ณผ์‘๊ณ ์ƒํƒœ ๊ด€๋ฆฌ (management of hypercoagulability)
โ‘ข ๊ณ ํ˜ˆ์•• ์น˜๋ฃŒ (antihypertensive therapy
โ‘ฃ ๋ถ€์ข…, ๋ณต์ˆ˜ ๊ด€๋ฆฌ (managing edema or ascites)
Specific treatment
Management of ICGN
Management of Amyloidosis
Complication management

1)

Prognosis